1、[22] LI H, SU Q, LI B, et al. High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration[J]. J Cell Mol Med, 2020, 24(8): 4452-4465.[22] LI H, SU Q, LI B, et al. High expression of WTAP leads to poor prognosis of gastric cancer by influencing tumour-associated T lymphocyte infiltration[J]. J Cell Mol Med, 2020, 24(8): 4452-4465.
2、[21] JO H J, SHIM H E, HAN M E, et al. WTAP regulates migration and invasion of cholangiocarcinoma cells[J]. J Gastroenterol, 2013, 48(11): 1271-1282.[21] JO H J, SHIM H E, HAN M E, et al. WTAP regulates migration and invasion of cholangiocarcinoma cells[J]. J Gastroenterol, 2013, 48(11): 1271-1282.
3、[20] CHEN L, WANG X. Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis[J]. Oncol Lett, 2018, 16(6): 6966-6970.[20] CHEN L, WANG X. Relationship between the genetic expression of WTAP and bladder cancer and patient prognosis[J]. Oncol Lett, 2018, 16(6): 6966-6970.
4、[19] CHEN Y, PENG C, CHEN J, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019, 18(1): 127-145.[19] CHEN Y, PENG C, CHEN J, et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1[J]. Mol Cancer, 2019, 18(1): 127-145.
5、[18] SORCI M, IANNIELLO Z, CRUCIANI S, et al. METTL3 regulates WTAP protein homeostasis[J]. Cell Death Dis, 2018, 9(8): 796-807.[18] SORCI M, IANNIELLO Z, CRUCIANI S, et al. METTL3 regulates WTAP protein homeostasis[J]. Cell Death Dis, 2018, 9(8): 796-807.
6、[17] PING X L, SUN B F, WANG L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J]. Cell Res, 2014, 24(2): 177-189.[17] PING X L, SUN B F, WANG L, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase[J]. Cell Res, 2014, 24(2): 177-189.
7、[16] LIU J, SUN G, PAN S, et al. The Cancer Genome Atlas (TCGA) based m(6)A methylation-related genes predict prognosis in hepatocellular carcinoma[J]. Bioengineered, 2020, 11(1): 759-768.[16] LIU J, SUN G, PAN S, et al. The Cancer Genome Atlas (TCGA) based m(6)A methylation-related genes predict prognosis in hepatocellular carcinoma[J]. Bioengineered, 2020, 11(1): 759-768.
8、[15] ZHU D, ZHOU J, ZHAO J, et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling[J]. J Cell Physiol, 2019, 234(6): 8899-8907.[15] ZHU D, ZHOU J, ZHAO J, et al. ZC3H13 suppresses colorectal cancer proliferation and invasion via inactivating Ras-ERK signaling[J]. J Cell Physiol, 2019, 234(6): 8899-8907.
9、[14] TANG J, WANG F, CHENG G, et al. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability[J]. J Exp Clin Cancer Res, 2018, 37(1): 40-51.[14] TANG J, WANG F, CHENG G, et al. Wilms' tumor 1-associating protein promotes renal cell carcinoma proliferation by regulating CDK2 mRNA stability[J]. J Exp Clin Cancer Res, 2018, 37(1): 40-51.
10、[13] WANG H, LIANG L, DONG Q, et al. Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma[J]. Theranostics, 2018, 8(10): 2814-2829.[13] WANG H, LIANG L, DONG Q, et al. Long noncoding RNA miR503HG, a prognostic indicator, inhibits tumor metastasis by regulating the HNRNPA2B1/NF-κB pathway in hepatocellular carcinoma[J]. Theranostics, 2018, 8(10): 2814-2829.
11、[12] YU P F, KANG A R, JING L J, et al. Long non-coding RNA CACNA1G-AS1 promotes cell migration, invasion and epithelial-mesenchymal transition by HNRNPA2B1 in non-small cell lung cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(4): 993-1002.[12] YU P F, KANG A R, JING L J, et al. Long non-coding RNA CACNA1G-AS1 promotes cell migration, invasion and epithelial-mesenchymal transition by HNRNPA2B1 in non-small cell lung cancer[J]. Eur Rev Med Pharmacol Sci, 2018, 22(4): 993-1002.
12、[11] VILLARROYA-BELTRI C, GUTIERREZ-VAZQUEZ C, SANCHEZ-CABO F, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs[J]. Nat Commun, 2013, 4(1): 2980-2989.[11] VILLARROYA-BELTRI C, GUTIERREZ-VAZQUEZ C, SANCHEZ-CABO F, et al. Sumoylated hnRNPA2B1 controls the sorting of miRNAs into exosomes through binding to specific motifs[J]. Nat Commun, 2013, 4(1): 2980-2989.
13、[10] ALARCON C R, GOODARZI H, LEE H, et al. HNRNPA2B1is a mediator of m(6)A-dependent nuclear rna processing events[J]. Cell, 2015, 162(6): 1299-1308.[10] ALARCON C R, GOODARZI H, LEE H, et al. HNRNPA2B1is a mediator of m(6)A-dependent nuclear rna processing events[J]. Cell, 2015, 162(6): 1299-1308.
14、 HE L, LI H, WU A, et al. Functions of N6-methyladenosine and its role in cancer[J]. Mol Cancer, 2019, 18(1): 176-190.[9] LAN Q, LIU P Y, HAASE J, et al. Thecritical role of RNA m(6)A methylation in cancer[J]. Cancer Res, 2019, 79(7): 1285-1292. HE L, LI H, WU A, et al. Functions of N6-methyladenosine and its role in cancer[J]. Mol Cancer, 2019, 18(1): 176-190.[9] LAN Q, LIU P Y, HAASE J, et al. Thecritical role of RNA m(6)A methylation in cancer[J]. Cancer Res, 2019, 79(7): 1285-1292.
15、 MAITY A, DAS B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases[J]. FEBS J, 2016, 283(9): 1607-1630. MAITY A, DAS B. N6-methyladenosine modification in mRNA: machinery, function and implications for health and diseases[J]. FEBS J, 2016, 283(9): 1607-1630.
16、 CHEN J, FANG X, ZHONG P, et al. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction[J]. RNA Biol, 2019, 16(8): 991-1000. CHEN J, FANG X, ZHONG P, et al. N6-methyladenosine modifications: interactions with novel RNA-binding proteins and roles in signal transduction[J]. RNA Biol, 2019, 16(8): 991-1000.
17、 LUO J, LIU H, LUAN S, et al. Aberrant regulation of mRNA m6A modification in cancer development[J]. Int J Mol Sci, 2018, 19(9): 2515-2526. LUO J, LIU H, LUAN S, et al. Aberrant regulation of mRNA m6A modification in cancer development[J]. Int J Mol Sci, 2018, 19(9): 2515-2526.
18、 CHEN X Y, ZHANG J, ZHU J S. The role of m6A RNA methylation in human cancer[J]. Mol Cancer, 2019, 18(1): 103-111. CHEN X Y, ZHANG J, ZHU J S. The role of m6A RNA methylation in human cancer[J]. Mol Cancer, 2019, 18(1): 103-111.
19、 OTTEVANGER P B. Ovarian cancer stem cells more questions than answers[J]. Semin Cancer Biol, 2017, 44(1): 67-71. OTTEVANGER P B. Ovarian cancer stem cells more questions than answers[J]. Semin Cancer Biol, 2017, 44(1): 67-71.
20、 KOSSAI M, LEARY A, SCOAZEC J Y, et al. Ovarian cancer: a heterogeneous disease[J]. Pathobiology, 2018, 85(1-2): 41-49. KOSSAI M, LEARY A, SCOAZEC J Y, et al. Ovarian cancer: a heterogeneous disease[J]. Pathobiology, 2018, 85(1-2): 41-49.
21、 WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41(1): 3-14. WEBB P M, JORDAN S J. Epidemiology of epithelial ovarian cancer[J]. Best Pract Res Clin Obstet Gynaecol, 2017, 41(1): 3-14.
